Taimei Technology, a Shanghai-Jiaxing SAAS company, completed a $212 million Series E/E+ round to advance its cloud AI-based suite of clinical trial programs. The company says its platform enables clinical research collaboration between sponsors, sites, CROs, patients, regulatory agencies and third-party providers. Founded in 2013, Taimei already offers six technology-enabled programs: data management, project management, electronic regulatory submission, central medical imaging, pharmacovigilance and drug logistics. It plans to expand into other areas of life science R&D.
Source: China Biotoday